Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 10 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 506879 | NSE: GUJTHEM

Gujarat Themis Biosyn Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2024, 10:34 pm

Market Cap 3,565 Cr.
Current Price 327
High / Low390/108
Stock P/E67.6
Book Value 20.5
Dividend Yield0.20 %
ROCE45.0 %
ROE33.8 %
Face Value 1.00
PEG Ratio5.37

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Gujarat Themis Biosyn Ltd

Competitors of Gujarat Themis Biosyn Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,565 Cr. 327390/10867.6 20.50.20 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 61.1 Cr. 82.394.9/22.723.4 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 25.8 Cr. 17.619.5/7.6033.6 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 91.3 Cr. 121155/87.014.2 51.80.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,431 Cr. 1,0961,335/62031.7 2072.05 %28.1 %21.1 % 2.00
Industry Average20,212.24 Cr1,274.5061.72190.310.31%16.78%15.93%6.64

All Competitor Stocks of Gujarat Themis Biosyn Ltd

Quarterly Result

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Sales35192945482828504039423935
Expenses1791622231613262321212019
Operating Profit18101323241214241717211915
OPM %53%53%45%51%51%43%52%47%42%45%50%48%44%
Other Income1121122111110
Interest0000000000000
Depreciation1111111111111
Profit before tax18101424251316241718211814
Tax %25%26%29%25%26%26%25%26%26%26%24%26%26%
Net Profit1471018191012181313161311
EPS in Rs1.270.650.901.631.720.901.071.631.151.191.461.210.97

Last Updated: November 6, 2024, 6:35 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:18 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales283031333639418591115148170159
Expenses25242527303334535057759185
Operating Profit3676667324058747974
OPM %11%21%21%19%17%16%18%37%45%51%50%46%46%
Other Income00-00002234744
Interest1100000111000
Depreciation1111111122344
Profit before tax1555558314159777973
Tax %0%0%0%0%10%20%22%24%26%26%25%25%
Net Profit1555446243044585955
EPS in Rs0.100.420.420.420.400.360.592.172.774.005.325.435.01
Dividend Payout %0%0%0%0%0%0%0%10%0%37%14%12%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)400.00%0.00%0.00%-20.00%0.00%50.00%300.00%25.00%46.67%31.82%1.72%
Change in YoY Net Profit Growth (%)0.00%-400.00%0.00%-20.00%20.00%50.00%250.00%-275.00%21.67%-14.85%-30.09%

Gujarat Themis Biosyn Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:19%
5 Years:33%
3 Years:23%
TTM:6%
Compounded Profit Growth
10 Years:29%
5 Years:56%
3 Years:25%
TTM:2%
Stock Price CAGR
10 Years:64%
5 Years:119%
3 Years:62%
1 Year:172%
Return on Equity
10 Years:%
5 Years:45%
3 Years:41%
Last Year:34%

Last Updated: Unknown

Balance Sheet

Last Updated: October 15, 2024, 1:29 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital777777777777
Reserves-17-13-8-31511356396142194
Borrowings1196341685103
Other Liabilities1713989881414181717
Total Liabilities181615152120336488122166221
Fixed Assets12111091111151719193338
CWIP000000102132191
Investments000000000000
Other Assets655511101747679011392
Total Assets181615152120336488122166221

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 0434361111403964
Cash from Investing Activity -3-0-0-1-3-1-6-3-2-30-20-55
Cash from Financing Activity 2-3-3-3-0-452-5-14-13-9
Net Cash Flow-01-1-0010-03-460

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-8.00-3.001.003.002.005.001.0024.0035.0057.0074.0076.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days371528247126528759804458
Inventory Days587819414425520133
Days Payable1,4989472408414513199
Cash Conversion Cycle-1,40315282471-8445241119189114-7
Working Capital Days-172-128-76-69-30-43-5842961589253
ROCE %208%121%81%55%42%45%84%67%67%61%45%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters74.99%74.99%74.99%75.00%75.00%75.00%75.00%75.00%70.87%70.87%70.87%70.87%
FIIs0.00%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.86%1.05%1.44%1.49%
DIIs0.31%0.31%0.31%0.03%0.03%0.03%0.03%0.03%0.04%0.82%1.18%1.17%
Public24.70%24.70%24.69%24.98%24.96%24.95%24.95%24.96%28.23%27.26%26.52%26.47%
No. of Shareholders13,05913,91713,83014,90416,55016,80417,37319,84628,65529,57630,28031,271

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal BSE Healthcare ETF4380.090.024382024-11-070%

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.005.005.005.005.00
Basic EPS (Rs.)8.1439.9030.0320.7716.30
Diluted EPS (Rs.)8.1439.9030.0320.7716.30
Cash EPS (Rs.)8.6341.6731.5621.9617.23
Book Value[Excl.RevalReserv]/Share (Rs.)27.72102.6671.1148.1429.04
Book Value[Incl.RevalReserv]/Share (Rs.)27.72102.6671.1148.1429.04
Dividend / Share (Rs.)1.005.4011.001.651.65
Revenue From Operations / Share (Rs.)23.38102.5479.0562.3358.59
PBDIT / Share (Rs.)11.4455.2342.7429.4223.09
PBIT / Share (Rs.)10.9553.4641.2028.2322.15
PBT / Share (Rs.)10.9253.3240.6328.1421.51
Net Profit / Share (Rs.)8.1439.9030.0320.7716.30
PBDIT Margin (%)48.9353.8654.0647.1939.40
PBIT Margin (%)46.8552.1352.1245.2837.80
PBT Margin (%)46.7151.9951.3945.1436.71
Net Profit Margin (%)34.8338.9137.9833.3227.81
Return on Networth / Equity (%)29.3738.8642.2243.1456.10
Return on Capital Employeed (%)38.8251.4156.8256.6168.85
Return On Assets (%)26.7534.8535.6134.1936.94
Long Term Debt / Equity (X)0.000.000.000.000.07
Total Debt / Equity (X)0.000.000.000.000.07
Asset Turnover Ratio (%)0.871.031.091.191.76
Current Ratio (X)2.943.984.574.001.65
Quick Ratio (X)2.743.033.893.621.31
Inventory Turnover Ratio (X)2.862.272.462.614.85
Dividend Payout Ratio (NP) (%)11.6621.0523.317.940.00
Dividend Payout Ratio (CP) (%)11.0020.1522.177.510.00
Earning Retention Ratio (%)88.3478.9576.6992.060.00
Cash Earning Retention Ratio (%)89.0079.8577.8392.490.00
Interest Coverage Ratio (X)362.56399.8175.01329.8236.33
Interest Coverage Ratio (Post Tax) (X)259.13289.8353.70233.8726.64
Enterprise Value (Cr.)2869.27987.92579.63268.24142.31
EV / Net Operating Revenue (X)16.906.635.052.961.67
EV / EBITDA (X)34.5312.319.336.284.24
MarketCap / Net Operating Revenue (X)16.946.695.153.271.66
Retention Ratios (%)88.3378.9476.6892.050.00
Price / BV (X)14.296.695.734.233.35
Price / Net Operating Revenue (X)16.946.695.153.271.66
EarningsYield0.020.050.070.100.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Gujarat Themis Biosyn Ltd as of November 10, 2024 is: 469.34

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 10, 2024, Gujarat Themis Biosyn Ltd is Undervalued by 43.53% compared to the current share price ₹327.00

Intrinsic Value of Gujarat Themis Biosyn Ltd as of November 10, 2024 is: 528.40

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 10, 2024, Gujarat Themis Biosyn Ltd is Undervalued by 61.59% compared to the current share price 327.00

Last 5 Year EPS CAGR: 12.58%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 73.00%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -11.25, which is a positive sign.
  3. The stock has a low average Cash Conversion Cycle of -16.58, which is a positive sign.
  4. The company has higher reserves (42.17 cr) compared to borrowings (4.75 cr), indicating strong financial stability.
  5. The company has shown consistent growth in sales (77.38 cr) and profit (30.31 cr) over the years.

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Themis Biosyn Ltd:
      1. Net Profit Margin: 34.83%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: 38.82% (Industry Average ROCE: 16.62%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 29.37% (Industry Average ROE: 15.49%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): 259.13
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 2.74
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 67.6 (Industry average Stock P/E: 48.7)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: 0
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Gujarat Themis Biosyn Ltd. is a Public Limited Listed company incorporated on 11/12/1981 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1981PLC004878 and registration number is 004878. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 114.85 Cr. and Equity Capital is Rs. 7.26 Cr. for the Year ended 31/03/2022.
    INDUSTRYADDRESSCONTACT
    PharmaceuticalsPlot NO. 69-C, G.I.D.C., Valsad District Gujarat 396195gtblmumbai@gtbl.in
    http://www.gtbl.in
    Management
    NamePosition Held
    Dr. Dinesh S PatelChairman & Non-Exe.Director
    Dr. Sachin D PatelPromoter Non-Exe.Director
    Mr. Vijay AgarwalInd. Non-Executive Director
    Dr. Vikram D SanghviInd. Non-Executive Director
    Mr. Siddharth Y KusumgarInd. Non-Executive Director
    Mrs. Kirandeep Kaur MadanInd. Non-Executive Director

    FAQ

    What is the latest fair value of Gujarat Themis Biosyn Ltd?

    The latest fair value of Gujarat Themis Biosyn Ltd is ₹469.34.

    What is the Market Cap of Gujarat Themis Biosyn Ltd?

    The Market Cap of Gujarat Themis Biosyn Ltd is 3,565 Cr..

    What is the current Stock Price of Gujarat Themis Biosyn Ltd as on 10 November 2024?

    The current stock price of Gujarat Themis Biosyn Ltd as on 10 November 2024 is 327.

    What is the High / Low of Gujarat Themis Biosyn Ltd stocks in FY 2024?

    In FY 2024, the High / Low of Gujarat Themis Biosyn Ltd stocks is 390/108.

    What is the Stock P/E of Gujarat Themis Biosyn Ltd?

    The Stock P/E of Gujarat Themis Biosyn Ltd is 67.6.

    What is the Book Value of Gujarat Themis Biosyn Ltd?

    The Book Value of Gujarat Themis Biosyn Ltd is 20.5.

    What is the Dividend Yield of Gujarat Themis Biosyn Ltd?

    The Dividend Yield of Gujarat Themis Biosyn Ltd is 0.20 %.

    What is the ROCE of Gujarat Themis Biosyn Ltd?

    The ROCE of Gujarat Themis Biosyn Ltd is 45.0 %.

    What is the ROE of Gujarat Themis Biosyn Ltd?

    The ROE of Gujarat Themis Biosyn Ltd is 33.8 %.

    What is the Face Value of Gujarat Themis Biosyn Ltd?

    The Face Value of Gujarat Themis Biosyn Ltd is 1.00.

    About the Author

    Author Avatar
    Getaka

    Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gujarat Themis Biosyn Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE